Search PubMed⌕ Search

Biomedical subjects

Iu A Pytel'

Publications and source records attributed to Iu A Pytel'.

At least 127 records · Page 7Linked to original sources
PubMedDate not supplied

[Protamine sulfate-induced resistance to the hypoglycemic effect of insulin].

Administration of protamine sulfate in a dose (0.9-1.1 mg/200 g) sufficient for binding reactive circulatory heparin provokes in rats the status of temporary resistance to the hypoglycemic action of both exogenous and endogenous insulin. This effect occurs after protamine sulfate administration 5-30 minutes prior to insulin in doses of 0.2-2.4 Units/200 g, respectively, or release of endogenous heparin stimulated by sugar load. As the time interval between administration of protamine sulfate and administration (release) of insulin is prolonged or shortened, the status of resistance does not develop. Protamine sulfate does not produce any effect on the blood concentration of immunoreactive insulin. Similarly to protamine sulfate, the resistance to the hypoglycemic action of insulin may be also provoked by the synthetic heparin antagonist, 2,5-ionene that binds heparin, forming a stable polyelectrolyte complex ionene-heparin. Administration of a sufficient heparin dose (10 Units/200 g) may interrupt the protamine sulfate-induced resistance, which manifests in the recurrence of the hypoglycemic action of insulin. There are reasons to assume that the presence of reactive heparin in the circulation is necessary for insulin reception by target tissues.

Animals↗
PubMedDate not supplied

[Age-related characteristics of the manifestation of the diabetogenic factor in the blood of animals maintained on natural and atherogenic diets].

The diabetogenic activity was studied in the blood plasma of rats of different age, kept on the natural and atherogenic diet. The relationship between the diabetogenic factor presence and functional condition of the anticoagulating system was investigated. The plasma of rat donors, examined for the presence of diabetogenic factor in their blood, was transfused to normal rat recipients (three transfusions of 1 ml per 200 g body weight daily). The activity of diabetogenic factor was determined according to a hyperglycemia degree in the blood of normal rat recipients. It was found that the blood plasma of old animals, kept on the natural diet, contains heparin-neutralizing diabetogenic factor. In middle-aged animals, kept on the atherogenic diet for a long time, the arising of more active diabetogenic factor in the blood is accelerated. The degree of the diabetogenic effect development in animal donors is directly dependent on their age and the function depression extent of the second anticoagulative system.

Aging↗
PubMedDate not supplied

[Experimental analysis of the pathophysiological significance of the "diabetogenic factor" present in the blood of animals with alloxan diabetes].

Hyperglycemia, induced by the disorder of Langerhans' islet structure and function, and hyperuricemia caused by purine metabolism pathological changes, appeared in the animals with experimental diabetes provoked by a single alloxan injection. As a result, endogenous alloxan-like factor, forming chronic diabetogenic background in the organism, arises and persists in the blood of the animals tested. Under these conditions, heparin exerts preventive and therapeutic effects due to alloxan or endogenous alloxan-like factor binding into complexes devoid of toxic activity.

Alloxan↗
PubMedDate not supplied

[Diabetogenic factor in the blood plasma in diabetes mellitus].

The blood plasma of rats with stable alloxan diabetes, injected three times in appropriate intravenous doses to intact rats, provoked in the rats-recipients hyperglycemia and hyperuricemia, persisted within 14 days. Under the same conditions the blood plasma of patients with diabetes mellitus induced hyperglycemia in the rats-recipients without hyperuricemia development during the same time period. A preliminary intravenous injection of heparin in a dose of 100 E (5 minutes before injecting the plasma of rats with alloxan diabetes or the plasma of patients with diabetes mellitus) completely prevented hyperglycemia and hyperuricemia development in the recipients. Intravenous injections of the blood plasma of healthy animals and humans did not provoke hyperglycemia and hyperuricemia arising in the rats-recipients. It is concluded, that in the blood plasma of animals with alloxan diabetes and in patients with diabetes mellitus the diabetogenic factor is present, being deactivated under heparin effect.

Animals↗